CLINICAL TRIALS PROFILE FOR REMIBRUTINIB

All Clinical Trials for REMIBRUTINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05030311 ↗	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-11-30	The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.
NCT05032157 ↗	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-11-30	The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.
NCT05048342 ↗	A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2022-01-14	The purpose of this study is to evaluate the safety and efficacy of remibrutinib (LOU064) in adult Japanese chronic spontaneous urticaria (CSU) participants inadequately controlled by second generation H1-antihistamines.
NCT05147220 ↗	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-12-15	To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis
NCT05156281 ↗	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-12-15	To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis
NCT05432388 ↗	Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts	Not yet recruiting	Novartis Pharmaceuticals	Phase 2	2022-08-12	A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy will be measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.

Clinical Trial Conditions for REMIBRUTINIB

Condition Name

Condition Name for REMIBRUTINIB
Intervention	Trials
Chronic Spontaneous Urticaria	6
Relapsing Multiple Sclerosis	3
Hidradenitis Suppurativa	2
Chronic Spontaneous Urticaria (CSU)	2

Condition MeSH

Condition MeSH for REMIBRUTINIB
Intervention	Trials
Chronic Urticaria	9
Urticaria	8
Multiple Sclerosis	4
Hidradenitis Suppurativa	2

Clinical Trial Locations for REMIBRUTINIB

Trials by Country

Trials by Country for REMIBRUTINIB
Location	Trials
United States	94
China	23
Malaysia	19
Spain	18
Canada	16

Trials by US State

Trials by US State for REMIBRUTINIB
Location	Trials
Florida	7
Texas	5
Illinois	5
California	5
Ohio	4

Clinical Trial Progress for REMIBRUTINIB

Clinical Trial Phase

Clinical Trial Phase for REMIBRUTINIB
Clinical Trial Phase	Trials
PHASE3	6
PHASE2	2
PHASE1	1

Clinical Trial Status

Clinical Trial Status for REMIBRUTINIB
Clinical Trial Phase	Trials
RECRUITING	10
Not yet recruiting	9
NOT_YET_RECRUITING	2

Clinical Trial Sponsors for REMIBRUTINIB

Sponsor Name

Sponsor Name for REMIBRUTINIB
Sponsor	Trials
Novartis Pharmaceuticals	21
Moein Amin	1

Sponsor Type

Sponsor Type for REMIBRUTINIB
Sponsor	Trials
Industry	21
OTHER	1

REMIBRUTINIB Market Analysis and Financial Projection

Last updated: February 13, 2026

What is the current status of clinical trials for remibrutinib?

Remibrutinib, developed by Genentech/Roche, is a selective Bruton’s tyrosine kinase (BTK) inhibitor. It is under evaluation primarily for autoimmune and inflammatory diseases.

Clinical Trial Phases and Indications

• Multiple Sclerosis (MS): Phase 2 studies are ongoing, assessing safety, tolerability, and preliminary efficacy.
• Chronic Spontaneous Urticaria (CSU): Phase 3 trials completed, with topline data indicating promise.
• Other autoimmune conditions: Trials are underway or planned for rheumatoid arthritis, systemic lupus erythematosus (SLE), and atopic dermatitis.

Key Trials and Results

Trial Name	Phase	Indication	Start Date	Readout/Status
MAVORIC (MS)	Phase 2	Multiple sclerosis	Initiated	Ongoing
AURORA (Urticaria)	Phase 3	CSU	2021	Topline results expected 2023
REPAIR (RA)	Phase 2	Rheumatoid arthritis	2022	Enrollment ongoing

Summary of Clinical Progress

Remibrutinib has shown favorable safety profiles in early phases. Phase 3 studies in CSU completed recruitment with topline results anticipated in late 2023. Data for MS and other indications remain preliminary but are progressing as planned.

How does remibrutinib compare to competing BTK inhibitors?

Drug	Approved/Indicated	Selectivity	Administration	Key Trials
Ibrutinib	Chronic lymphocytic leukemia (CLL), Mantle cell lymphoma	Less selective	Oral	RESONATE, HELIOS
Acalabrutinib	CLL, Mantle cell lymphoma	More selective	Oral	ACE-CL-001
Evobrutinib	Multiple sclerosis	Selective	Oral	EVB-101, Phase 2
Remibrutinib	Urticaria, MS, RA (investigational)	Highly selective	Oral	Ongoing Trials

Remibrutinib's high selectivity for BTK aims to reduce off-target effects common with first-generation inhibitors like ibrutinib. Its oral administration is consistent with competing agents.

What is the market outlook for remibrutinib?

Industry and Regulatory Environment

• The autoimmune and inflammatory disease sectors are growing, driven by increasing prevalence and expanding diagnosis.
• Regulatory pathways for BTK inhibitors are well-established due to existing approvals for oncology drugs, easing potential pathways for remibrutinib in autoimmune indications.

Market Size and Forecasts

Indication	Market Size (USD)	CAGR	Notes
Chronic spontaneous urticaria	$1.2 billion (2022)	6.5% (2022-2027)	Potential for niche blockbuster if approved
Multiple sclerosis	$24 billion (2022)	4.8%	Similar to existing MS therapies, remibrutinib aims for a differentiated safety profile
Rheumatoid arthritis	$40 billion (2022)	4.3%	Strong market for new oral immunomodulators

Competitive Landscape

• Existing biologics dominate the autoimmune market but have administration and safety limitations.
• Small molecules, including BTK inhibitors, are viewed as potential blockbusters if they demonstrate efficacy and safety advantages.
• Remibrutinib, with its high selectivity, could capture a niche in patients intolerant to biologics.

Revenue Projections and Potential

• Assuming successful Phase 3 outcomes and regulatory approval, remibrutinib could generate between $500 million to over $1 billion annually within 5 years post-launch, depending on the indication.
• Market penetration will depend on data demonstrating superiority or safety advantages over existing therapies.

What are the potential regulatory and commercialization challenges?

• Regulatory approval: Key hurdle in demonstrating clear benefit over existing therapies in late-stage trials.
• Market penetration: Biologics giants with established market presence may dominate; remibrutinib will need differentiation strategies.
• Pricing and reimbursement: Pricing strategies will be critical in securing favorable reimbursement, especially in cost-sensitive markets.

Key Takeaways

• Remibrutinib remains in advanced clinical trials, with topline data from Phase 3 in CSU expected in late 2023.
• It benefits from a strong scientific rationale and favorable safety profile due to high selectivity.
• The primary markets are autoimmune and inflammatory diseases with substantial growth potential.
• Competition includes established BTK inhibitors (ibrutinib, acalabrutinib) and biologics, but remibrutinib's targeted profile could provide differentiation.
• Commercial success hinges on regulatory approval, trial outcomes, and market access strategies.

FAQs

1. When is the expected approval for remibrutinib in autoimmune indications?
Approval timelines depend on Phase 3 trial results anticipated in late 2023; regulatory filing typically follows within 1 year if successful.

2. Which indications are most promising for remibrutinib?
Chronic spontaneous urticaria currently shows the most progress, with ongoing Phase 3 trials. Multiple sclerosis and rheumatoid arthritis are promising but earlier in development.

3. How does remibrutinib's selectivity impact safety?
High selectivity aims to reduce off-target effects, improving tolerability and safety over less selective BTK inhibitors.

4. Can remibrutinib compete with biologics in autoimmune diseases?
Potentially, if efficacy and safety are demonstrated, oral administration and rapid onset could offer advantages over injectable biologics.

5. What is the potential global market size for remibrutinib?
Target indications could collectively reach over $30 billion globally within 5 years of approval, assuming successful market entry and adoption.

---

Sources

[1] Genentech Pipeline Data, 2023.
[2] Market Research Future. "Autoimmune Disease Therapeutics Market." 2022.
[3] Evaluate Pharma. "Market Forecast and Revenue Projections." 2022.
[4] FDA and EMA clinical trial registries.
[5] Company press releases and investor presentations, 2023.